Assignee
NANJING IASO BIOTECHNOLOGY CO LTD
CN·3 granted patents·3 pending applications·0 citations·filing 2020–2022
Top patents by PatentIndex Score
6 records- 0154US2024050568A1Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereofNANJING IASO BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 0251US2024092925A1Cd5-targeting fully humanized antibodyNANJING IASO BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 0344US12583931B2Antibody and chimeric antigen receptor (CAR) binding to CD70, and application thereofNANJING IASO BIOTECHNOLOGY CO LTD·Filed 2021·Granted Mar 24, 2026·0 cites·18 claims
- 0443US12448453B2Fully human anti-human CD22 chimeric antigen receptor and application thereofNANJING IASO BIOTECHNOLOGY CO LTD·Filed 2021·Granted Oct 21, 2025·0 cites·17 claims
- 0543US2024002505A1Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereofNANJING IASO BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 0636US12516117B2Fully human antibody targeting CD19 and application thereofNANJING IASO BIOTECHNOLOGY CO LTD·Filed 2020·Granted Jan 6, 2026·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when NANJING IASO BIOTECHNOLOGY CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →